InflaRx N.V.
IFRX
Price:
$2.51
Market Cap:
$141.69M
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune dis...[Read more]
Industry
Biotechnology
IPO Date
2017-11-07
Stock Exchange
NASDAQ
Ticker
IFRX
PE Ratio
[-2.46]
ROE
[-65.54%]
Current Ratio
[5.31]
Dividend Yield
[0%]
Enterprise Value
[116.38M]
Dividend History
The ROE as of December 2024 (TTM) for InflaRx N.V. (IFRX) is -65.54%
According to InflaRx N.V.’s latest financial reports and current stock price. The company's current ROE is -65.54%. This represents a change of 280.33% compared to the average of -17.23% of the last 4 quarters.
InflaRx N.V. (IFRX) Historical ROE (quarterly & annually)
How has IFRX ROE performed in the past?
The mean historical ROE of InflaRx N.V. over the last ten years is -20.32%. The current -65.54% ROE has changed 222.49% with respect to the historical average. Over the past ten years (40 quarters), IFRX's ROE was at its highest in in the December 2016 quarter at 16.98%. The ROE was at its lowest in in the September 2024 quarter at -26.73%.
Average
-20.32%
Median
-30.61%
Minimum
-46.42%
Maximum
34.80%
InflaRx N.V. (IFRX) ROE by Quarter and Year
Discovering the peaks and valleys of InflaRx N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 135.72%
Maximum Annual ROE = 34.80%
Minimum Annual Increase = -158.32%
Minimum Annual ROE = -46.42%
| Year | ROE | Change |
|---|---|---|
| 2023 | -41.56% | 35.78% |
| 2022 | -30.61% | -29.42% |
| 2021 | -43.36% | -0.72% |
| 2020 | -43.68% | -5.91% |
| 2019 | -46.42% | 135.72% |
| 2018 | -19.69% | -2.96% |
| 2017 | -20.29% | -158.32% |
| 2016 | 34.80% | 24.69% |
InflaRx N.V. (IFRX) Average ROE
How has IFRX ROE performed in the past?
The current ROE of InflaRx N.V. (IFRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-38.51%
5-year avg
-41.13%
10-year avg
-20.32%
InflaRx N.V. (IFRX) ROE vs. Peers
How is IFRX’s ROE compared to its peers?
InflaRx N.V.’s ROE is greater than Generation Bio Co. (-104.85%), greater than Kronos Bio, Inc. (-64.55%), greater than Erasca, Inc. (-42.26%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Kezar Life Sciences, Inc. (-59.73%), greater than Fulcrum Therapeutics, Inc. (-7.31%), greater than Passage Bio, Inc. (-72.53%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), less than Galera Therapeutics, Inc. (14.34%), greater than Inozyme Pharma, Inc. (-88.42%), less than Eledon Pharmaceuticals, Inc. (21.51%), greater than Icosavax, Inc. (-20.22%), greater than Ocuphire Pharma, Inc. (-30.19%), less than Reviva Pharmaceuticals Holdings, Inc. (1.15%), greater than Protalix BioTherapeutics, Inc. (-30.89%), greater than EyePoint Pharmaceuticals, Inc. (-43.01%), greater than SELLAS Life Sciences Group, Inc. (-629.45%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%),
| Company | ROE | Market cap |
|---|---|---|
| -104.85% | $71.47M | |
| -64.55% | $57.32M | |
| -42.26% | $726.61M | |
| -42.45% | $273.18M | |
| -26.83% | $2.80B | |
| -59.73% | $47.86M | |
| -7.31% | $245.42M | |
| -72.53% | $40.24M | |
| -32.99% | $107.54M | |
| 14.34% | $1.63M | |
| -88.42% | $188.22M | |
| 21.51% | $255.09M | |
| -20.22% | $769.04M | |
| -30.19% | $31.74M | |
| 1.15% | $82.91M | |
| -30.89% | $130.33M | |
| -43.01% | $500.28M | |
| -629.45% | $65.42M | |
| -62.68% | $433.13M | |
| -18.01% | $359.54M | |
| -58.83% | $68.63M | |
| -39.59% | $73.83M | |
| -54.45% | $599.59M |
Build a custom stock screener for InflaRx N.V. (IFRX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
InflaRx N.V. (IFRX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is InflaRx N.V.'s ROE?
How is the ROE calculated for InflaRx N.V. (IFRX)?
What is the highest ROE for InflaRx N.V. (IFRX)?
What is the 3-year average ROE for InflaRx N.V. (IFRX)?
What is the 5-year average ROE for InflaRx N.V. (IFRX)?
How does the current ROE for InflaRx N.V. (IFRX) compare to its historical average?